Navigation Links
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Date:5/21/2008

ommercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the ongoing clinical testing of voreloxin, potential safety and efficacy and commercial potential of voreloxin, planned additional clinical testing and development efforts, the timing of enrollment of patients in the company's clinical trials, the adoption of voreloxin as a nonproprietary name and the announcement of clinical results. Words such as "expect," "will," "opportunity," "plans," "could," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk tha
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
3. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
4. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... Device An ophthalmic diagnostic device is ... deficiency in the human visual pathway. Ophthalmic devices are ... cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... 2014 Leading events organizer UBM Live ... the seventh year to São Paulo, Brazil ... 2014. The event will co-locate with Food Ingredients South America ... meeting point for the pharmaceutical industry.      (Logo: ... pharmaceutical sales are now exploring the South America ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4
... , Breakthrough findings unveiled at the American Society of ... WASHINGTON, June 8 The American Society of Echocardiography ... to present their most-recent findings at its 20th Annual ... Center in Washington, DC. This year, NBA basketball ...
... at the 14th Congress of the European Hematology Association ... Disease , , BERLIN, June 8 Micromet, ... developing novel, proprietary antibodies for the treatment of cancer, ... ALL Study Group (GMALL) presented phase 2 clinical data ...
Cached Medicine Technology:New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients 2New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients 3New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5
(Date:7/25/2014)... (PRWEB) July 25, 2014 As reported by ... in War On Heroin (7/20), police in Salem, MA ... crack down on the recent heroin epidemic that has taken ... focuses on one heroin-related overdose case in which police were ... the victim's cell phone. By pretending to be the victim ...
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... Toronto, ON (PRWEB) July 25, 2014 Art ... demand, providing services to those in Toronto who are looking ... to a study done by the American Academy of ... March of 2014, interest in facial plastic surgery showed a ... nose jobs rose 10 percent, while hair transplants increased by ...
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2
... First Ladies of ... Rwanda and Zambia, LAKE FOREST, Calif., ... hosted by pastor and "The,Purpose Driven Life" author Dr. Rick Warren and ... beginning today through,Friday, Nov. 30 with a Youth Summit on Saturday, Dec. ...
... 28 Over the past few weeks,there has ... diabolical plan,between the meat industry and the USDA ... that have failed to be "non-negative" for E.,coli ... -- which includes cooking to the thermal death,stage ...
... liver disease, study finds , , WEDNESDAY, Nov. 28 ... the number of clotting cells, called platelets, in patients ... report. , The new drug is called eltrombopag, and ... thrombocytopenic purpura (ITP) were able to use the medication ...
... African-American men face an observable disadvantage versus Caucasian men ... only is prostate cancer detected later in African Americans, ... , Findings on the social and biological ... at the American Association for Cancer Research conference on ...
... may make it tougher for them to function socially, ... Children diagnosed with autism have more gray matter in ... a novel imaging technique to analyze brain structure. , ... make it harder for autistic children to learn how ...
... GREEN BAY, Wis., Nov. 28 Stress can ruin ... to NIH estimates, at least 60,million Americans annually suffer ... play a major role., "Stress and sleep are ... Health Sciences for Enzymatic Therapy (ETI). "But,many people don,t ...
Cached Medicine News:Health News:Global Summit on AIDS and the Church Begins Today and Concludes With Youth Summit on World AIDS Day: 2Health News:Global Summit on AIDS and the Church Begins Today and Concludes With Youth Summit on World AIDS Day: 3Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 2Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 3Health News:Drug May Help Reverse Clotting Deficiency 2Health News:Drug May Help Reverse Clotting Deficiency 3Health News:Genetic and behavioral differences add to prostate cancer disparities 2Health News:Genetic and behavioral differences add to prostate cancer disparities 3Health News:Genetic and behavioral differences add to prostate cancer disparities 4Health News:Genetic and behavioral differences add to prostate cancer disparities 5Health News:Autistic Children Have More Gray Matter in Brains 2Health News:Autistic Children Have More Gray Matter in Brains 3Health News:Autistic Children Have More Gray Matter in Brains 4Health News:Reduce Stress Hormones to Beat Sleep Problems 2
For use with WarmTouch® Warming Blankets for the prevention or treatment of hypothermia...
The Synoptiscope(L-2510HB) has a wide variety of functions including binocular function diagnosis and treatment....
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: